Balyasny Asset Management
MTNB icon

Balyasny Asset Management’s Matinas BioPharma MTNB Stock Holding History

Balyasny Asset Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,982
Closed -$63K – 3064
2022
Q3 		$63K Buy
+1,982
New +$77.8K ﹤0.01% 2452

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Balyasny Asset Management's MTNB Position: Q4 2022 in Review

Balyasny Asset Management sold out of Matinas BioPharma (MTNB) in Q4 2022, closing a stake of 1,982 shares — an estimated $63K sold.

Balyasny Asset Management first reported a position in MTNB in Q3 2022 and held it in 1 quarter. The position peaked at $63K in Q3 2022. 57 funds tracked by Wall St. Rank hold MTNB as of Q4 2022.

  • Balyasny Asset Management reported no remaining Matinas BioPharma position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 1,982 Matinas BioPharma shares in Q4 2022, an estimated $63K.
  • Balyasny Asset Management first reported a position in Matinas BioPharma in Q3 2022 and held it in 1 quarter.
  • Balyasny Asset Management's Matinas BioPharma position peaked at $63K in Q3 2022.
  • 57 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.